Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$92.60

-2.77 (-2.90%)

09:05
09/19/18
09/19
09:05
09/19/18
09:05

AbbVie's California lawsuit may have broader implications, says Credit Suisse

After the State of California has filed a lawsuit against AbbVie, accusing the company of paying kickbacks to doctors and using a network of nurses to illegally boost Humira prescriptions, Credit Suisse analyst Vamil Divan said he is "not surprised" by the stock's weakness given how leveraged it is to Humira sales and profit, and think there could be additional weakness as the story develops, especially if other states file similar lawsuits against the company. Additionally, he wonders how lawsuits like this may impact marketing practices across the industry. Divan maintains a cautious view on the stock with an Underperform rating and $85 price target, and says he continues to have concerns about the sustainability of Humira given the expected entry of multiple biosimilars in the EU next month expected biosimilar pressure in the U.S. starting in 2023.

ABBV AbbVie
$92.60

-2.77 (-2.90%)

08/22/18
PIPR
08/22/18
NO CHANGE
Target $130
PIPR
Overweight
AbbVie decision suggests positive Argenx data, says Piper Jaffray
AbbVie's (ABBV) decision to exercise an exclusive option to license Argenx's (ARGX) anti-GARP antibody, ARGX-115, suggests positive preclinical data, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst looks for investigational new drug application filing plans this year. He reiterates an Overweight rating on shares of Argenx with a $130 price target.
08/29/18
HCWC
08/29/18
NO CHANGE
Target $44
HCWC
Buy
AbbVie study of elagolix reduces risk for ObsEva, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes AbbVie's (ABBV) long-term safety extension study of elagolix in women with uterine fibroids reduces risk for ObsEva (OBSV). The long-term efficacy for elagolix should bode well for future development of ObsEva's linzagolix in uterine fibroids, since both drugs are gonadotropin-releasing hormone receptor antagonists and have thus far shown comparable potency in clinical studies, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on ObsEva with a $44 price target.
09/10/18
BTIG
09/10/18
INITIATION
Target $32
BTIG
Buy
Voyager Therapeutics assumed with a Buy at BTIG
BTIG analyst Thomas Shrader assumed Voyager Therapeutics (VYGR) with a Buy rating and a price target of $32, saying the company is an "attractive investment" based on its lead product for late-stage Parkinson's Disease patients and its "robust" adeno-associated viral technology platform. The analyst expects Voyager to be well served in its upcoming gene therapy market share competition and also cites the company's "productive FDA meetings"and the start of of a phase 2 trial. Shrader further notes that Voyager Therapeutics' latest Abbvie (ABBV) deal is a "vote of confidence" for its program.
09/19/18
PIPR
09/19/18
NO CHANGE
Target $100
PIPR
Neutral
Piper more worried about AbbVie co-pay accumulator risk than California suit
While shares of AbbVie may move lower today on news of California's insurance regulator suing the company over promotion of Humira, a more fundamental potential drag on Humira remains the advent of co-pay accumulators, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst sees the California lawsuit as more headline risk than anything but thinks "it may nevertheless serve as a minor overhang on shares." He points out that new research this week by Drug Channels suggests that more than one-third of commercial lives are enrolled in plans that have implemented copay accumulators for 2018, higher than his prior best estimate of 17%. Raymond keeps a Neutral rating on AbbVie with a $100 price target.

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$102.56

-0.41 (-0.40%)

04:57
10/15/18
10/15
04:57
10/15/18
04:57
Upgrade
Kansas City Southern rating change  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

8-Week Bill Announcement…

REFR

Research Frontiers

$1.73

0.03 (1.76%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Research Frontiers management to meet with Maxim »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

TEUM

Pareteum

$2.55

0.02 (0.79%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Pareteum management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 07

    Nov

  • 15

    Nov

IHRT

iHeartMedia

$0.00

(0.00%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen TMT analyst Vitanza to hold an analyst/industry conference call »

Technology, Media and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

OKE

Oneok

$64.99

-0.24 (-0.37%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Oneok management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

  • 31

    Oct

FDX

FedEx

$220.97

3.54 (1.63%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
FedEx management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

HRS

Harris

$154.88

0.61 (0.40%)

, LLL

L3 Technologies

$195.99

0.74 (0.38%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
L3 Technologies and Harris to hold a joint conference call »

The companies hold a…

HRS

Harris

$154.88

0.61 (0.40%)

LLL

L3 Technologies

$195.99

0.74 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 16

    Oct

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

NXST

Nexstar

$74.10

0.2 (0.27%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Nexstar management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 08

    Nov

  • 13

    Nov

SLDB

Solid Biosciences

$34.19

-0.15 (-0.44%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Solid Biosciences has a conference call hosted by JPMorgan »

JPMorgan Analyst Rama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

GOL

Gol Linhas

$7.38

0.27 (3.80%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Gol Linhas management to meet with Buckingham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 16

    Oct

ADBE

Adobe

$248.89

10.24 (4.29%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Adobe to host financial analyst meeting »

Financial Analyst Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

AET

Aetna

$200.91

1.83 (0.92%)

, CVS

CVS Health

$74.49

1.33 (1.82%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen healthcare analysts to hold an analyst/industry conference call »

Healthcare Analysts,…

AET

Aetna

$200.91

1.83 (0.92%)

CVS

CVS Health

$74.49

1.33 (1.82%)

ESRX

Express Scripts

$94.29

0.55 (0.59%)

CI

Cigna

$207.05

1.04 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 01

    Nov

AET

Aetna

$200.91

1.83 (0.92%)

, CVS

CVS Health

$74.49

1.33 (1.82%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Healthcare Analysts,…

AET

Aetna

$200.91

1.83 (0.92%)

CVS

CVS Health

$74.49

1.33 (1.82%)

ESRX

Express Scripts

$94.29

0.55 (0.59%)

CI

Cigna

$207.05

1.04 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 15

    Oct

  • 15

    Oct

  • 01

    Nov

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Morgan Stanley China auto analysts to hold analyst/industry conference call »

U.S. Autos & Shared…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Cowen pharmaceuticals analyst to hold an analyst/industry conference call »

Pharmaceuticals Analyst…

BPY

Brookfield Property

$19.57

0.06 (0.31%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Brookfield Property management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 01

    Nov

INTU

Intuit

$211.90

11.09 (5.52%)

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Intuit management to meet with RBC Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Oct

  • 21

    Oct

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Retail Sales to be reported at 08:30 »

September Retail Sales…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Retail Sales less autos to be reported at 08:30 »

September Retail Sales…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Business Inventories to be reported at 10:00 »

August Business…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
General news
Breaking General news story  »

3-Month Bill Auction to…

04:55
10/15/18
10/15
04:55
10/15/18
04:55
Conference/Events
Wedbush restaurants analyst to hold a luncheon »

Restaurants Analyst…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.